

New Zealand standardised oral formulation batch sheet

Sildenafil suspension 2 mg/mL (50 mL)											
Patient's name		Storage condition		In a refrigerator			At room temperature				
NHI				Temperature		2-8°C		≤ 25°C			
Date compounded	Date compounded		Shelf life		30 days			30 days			
Batch number	number		Recommended storage				N	May be stored at room temperature if this is more practical and temperatures greater than 25°C are avoided			
Ingredients required	and formula:		<u> </u>				•				
Ingredient	Supplier	Batch number	Expiry date	Star forn	•		Dis by	pensed	Checked by		
Sildenafil 100mg tablet (citrate)				1	L tablet						
Ora-Blend®	Perrigo			to	50 mL						
OR			_								
Ora-Plus®	Perrigo				25 mL						
Ora-Sweet®	Perrigo				25 mL						
Ora-Blend SF® or Ora-Sweet SF® (sugar free) can be substituted? No											
Calculations performed by											
Calculations checked by (pharmacist)											
Area cleared for processing by											
Instructions to compo	ound suspensio	n:									
1. If Ora-Blend® unavailable: Pre-mix the Ora-Plus® and Ora-Sweet® to form the diluent.											
2. Crush tablets in mortar to a fine powder.											
3. Add diluent (Ora-Blend® or prepared diluent) to form a smooth paste.											
4. Gradually add the diluent and transfer to the final measuring flask, rinsing the mortar well. Mix well.											
5. Make up to the final volume and mix well.											
6. Label and page	ckage product a	ppropriately.									
Labels											
Attach product label	and auxiliary lai	bels:						Label	checked by		



New Zealand standardised oral formulation batch sheet

Sildenafil suspension 2 mg/mL (50 mL)

Final yield		m	L	Checked by				
Final appearance of product		Pale blue suspension.						
Container		Amber plastic mission bottle.						
Compounded by		Name:	Signatu	ıre:	Date:			
Final check and product release		Name:	Signatu	ire:	Date:			
Special instructions: 1. Shake well before use. 2. Store in a refrigerator.								
References: 1. Nahata MC. Int J Pharm Compd, 2016; 20 (3): 247-249. 2. Nahata MC, Morosco RS, Brady MT. Am J Health Syst Pharm, 2006; 63 (3): 254-257.								
Prepared by	New Zealand Compounding Working Group							
Approved by	approved by							
Hosted by								
Version number			Version a	oproval date	01/02/2023			
Document review due	01/02/2025	5						

Disclaimer: this batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please read and familiarise yourself with the general guidance for compounding oral liquids (available on the PSNZ web site) before use. Information was considered accurate at the time of publication.